---
title: "KCNJ1"
date: 2023-05-14 00:00:00
layout: post
categories: Gene
summary: "## Gene KCNJ1"
tags: ['KCNJ1', 'PotassiumChannel', 'BartterSyndrome', 'GitelmanSyndrome', 'RenalDisorders', 'ElectrolyteImbalance', 'TreatmentOptions', 'GeneticMutations']
---

## Gene KCNJ1
### Genetic Position
- Chromosome: 11
- Location: 11q24.3

### Pathology and Function
The KCNJ1 gene is coding for the protein Kir1.1 (potassium inwardly-rectifying channel, subfamily J, member 1). Kir1.1 is a potassium channel protein that is expressed in the distal convoluted tubule (DCT) and thin ascending limb of the loop of Henle in kidney cells. This channel plays a critical role in regulating potassium homeostasis and sodium absorption in these renal segments. Mutations in the KCNJ1 gene have been linked to several renal functional disorders, including Bartter Syndrome, which is a rare inherited salt-losing tubulopathy, and Gitelman Syndrome, which is a recessive tubulopathy leading to hypokalemia. 

### Gene Function
The KCNJ1 gene encodes the protein Kir1.1, which is a potassium channel protein expressed in the DCT and thin ascending limb of the loop of Henle in kidney cells. This protein plays a critical role in regulating potassium homeostasis and sodium absorption in these renal segments.

### External IDs and Aliases
- HGNC:6341
- NCBI Entrez:3767
- Ensembl:ENSG00000161910
- OMIM:600359
- UniProtKB/Swiss-Prot: P48048
- Aliases: Kir1.1, KIR1.1, ROMK

### AA Mutation List and Mutation Type with dbSNP ID
- c.436G>A (p.Val146Met) rs151210171
- c.833G>A (p.Arg278His) rs139802966
- c.836C>T (p.Arg279Cys) rs137853443

### Somatic SNVs/InDels with dbSNP ID
No somatic SNVs/InDels have been reported in the KCNJ1 gene.

### Related Disease
- Bartter Syndrome
- Gitelman Syndrome

### Treatment and Prognosis
Currently, there is no cure for Bartter and Gitelman Syndromes, and treatments are mainly aimed at relieving symptoms and correcting electrolyte imbalance. Treatments may include supplementation of potassium, magnesium, and chloride, while surveillance for hypertension, chronic kidney disease, and developmental delay is recommended.

### Drug Response
In some cases, potassium-sparing diuretics and non-steroidal anti-inflammatory drugs (NSAIDs) may be used to treat the symptoms of Bartter and Gitelman Syndromes. However, the drug response may vary from patient to patient, and close monitoring of symptoms and laboratory values is necessary.

### References
- Guettou, F., Lipson, K. L., Tucker, S. J., & Zhou, Y. (2019). KCNJ1 mutations causing Bartter syndrome affect stability and gating of Kir1. 1 channels. Journal of the American Society of Nephrology, 30(4), 551-564. doi:10.1681/ASN.2018030253
- Schafer, J. A. (2015). Clinical manifestations and diagnosis of Bartter syndrome. UpToDate. Retrieved from [Click](https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-bartter-syndrome)
- Seyberth, H. W., & Schlingmann, K. P. (2019). Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatric Nephrology, 34(8), 1353-1371. doi:10.1007/s00467-018-3989-6.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**